ArticleThe Lancet. Public health2024
Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021.
Article in The Lancet. Public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Health impacts of electronic nicotine delivery systems: an umbrella review of systematic reviews.BMJ open · 2025Pooled it
- Impact of surgical margins status on survival outcomes in oral cavity squamous cell carcinoma: a systematic review and meta-analysis.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2025Pooled it
- Anticancer efficacy of Spiruchostatin A: current insights into histone deacetylase inhibition and oncologic applications.European journal of medical research · 2025Pooled it
- All-Cause and Cause-Specific Mortality in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- Cost-effectiveness of in-hospital motivational smoking cessation counselling and proactive referral to community-based follow-up.Addiction (Abingdon, England) · 2026Trial
- Electroacupuncture as a Non-Pharmacological Intervention for Nicotine Dependence: Evidence from a Randomized Clinical Trial.Therapeutics and clinical risk management · 2025Trial
- A community-based Daoyin program for health promotion: effects of the Qi and mind harmonizing method on body constitution for the health of older adults.Frontiers in public health · 2025Trial
- Cancer mortality predictions for 2026 in selected Asian countries and Australia with focus on prostate cancer.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026Article
- Global, regional, and national prevalence of second-hand smoke and attributable disease burden in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.The Lancet. Public health · 2026Article
- Global, Regional, and National Burden of Aortic Aneurysm, 1990-2021, and Projections to 2050.Journal of Korean medical science · 2026Article
- Global trends in gastric cancer burden among adolescents and young adults: A population-based observational study using GBD 2021 data.Medicine · 2026Observational
- Burden of ischemic stroke in China from 1990 to 2050: A systematic review and analysis of Global Burden of Disease Study 2021.Neuroprotection (Chichester, England) · 2026Article
- Sex inequality in disease burden attributable to smoking, secondhand smoke and chewing tobacco: A systematic analysis for the Global Burden of Disease Study 2023.EClinicalMedicine · 2026Article
- Global, regional, and national burden of colorectal cancer attributable to modifiable risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.Journal of gastrointestinal oncology · 2026Article
- Burden of stroke and its subtypes in young adults in Asia, 1990-2021: risk factors and future predictions.Stroke and vascular neurology · 2026Review
- Evaluation of the Feasibility and Acceptability of Perfect Fit, a Virtual Coach-Based mHealth Intervention for Smoking Cessation and Physical Activity in Adults: Mixed Methods Study.JMIR human factors · 2026Article
- Diabetes Burden in the Middle East and North Africa Region, 1990-2023: An Ecological Time-Trend Analysis of GBD Estimates.Medicina (Kaunas, Lithuania) · 2026Article
- Trends and projections of high body mass index-associated non-hodgkin lymphoma burden (1990-2040): A global burden of disease 2021 analysis.Annals of hematology · 2026Article
- Article
- Surgical outcomes and quality of life in octogenarians with early-stage non-small cell lung cancer: a prospective cohort study.Lancet regional health. Americas · 2026Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundSmoking is the leading behavioural risk factor for mortality globally, accounting for more than 175 million deaths and nearly 4·30 billion years of life lost (YLLs) from 1990 to 2021. The pace of decline in smoking prevalence has slowed in recent years for many countries, and although strategies have recently been proposed to achieve tobacco-free generations, none have been implemented to date. Assessing what could happen if current trends in smoking prevalence persist, and what could happen if additional smoking prevalence reductions occur, is important for communicating the effect of potential smoking policies.
methodsIn this analysis, we use the Institute for Health Metrics and Evaluation's Future Health Scenarios platform to forecast the effects of three smoking prevalence scenarios on all-cause and cause-specific YLLs and life expectancy at birth until 2050. YLLs were computed for each scenario using the Global Burden of Disease Study 2021 reference life table and forecasts of cause-specific mortality under each scenario. The reference scenario forecasts what could occur if past smoking prevalence and other risk factor trends continue, the Tobacco Smoking Elimination as of 2023 (Elimination-2023) scenario quantifies the maximum potential future health benefits from assuming zero percent smoking prevalence from 2023 onwards, whereas the Tobacco Smoking Elimination by 2050 (Elimination-2050) scenario provides estimates for countries considering policies to steadily reduce smoking prevalence to 5%. Together, these scenarios underscore the magnitude of health benefits that could be reached by 2050 if countries take decisive action to eliminate smoking. The 95% uncertainty interval (UI) of estimates is based on the 2·5th and 97·5th percentile of draws that were carried through the multistage computational framework.
findingsGlobal age-standardised smoking prevalence was estimated to be 28·5% (95% UI 27·9-29·1) among males and 5·96% (5·76-6·21) among females in 2022. In the reference scenario, smoking prevalence declined by 25·9% (25·2-26·6) among males, and 30·0% (26·1-32·1) among females from 2022 to 2050. Under this scenario, we forecast a cumulative 29·3 billion (95% UI 26·8-32·4) overall YLLs among males and 22·2 billion (20·1-24·6) YLLs among females over this period. Life expectancy at birth under this scenario would increase from 73·6 years (95% UI 72·8-74·4) in 2022 to 78·3 years (75·9-80·3) in 2050. Under our Elimination-2023 scenario, we forecast 2·04 billion (95% UI 1·90-2·21) fewer cumulative YLLs by 2050 compared with the reference scenario, and life expectancy at birth would increase to 77·6 years (95% UI 75·1-79·6) among males and 81·0 years (78·5-83·1) among females. Under our Elimination-2050 scenario, we forecast 735 million (675-808) and 141 million (131-154) cumulative YLLs would be avoided among males and females, respectively. Life expectancy in 2050 would increase to 77·1 years (95% UI 74·6-79·0) among males and 80·8 years (78·3-82·9) among females.
interpretationExisting tobacco policies must be maintained if smoking prevalence is to continue to decline as forecast by the reference scenario. In addition, substantial smoking-attributable burden can be avoided by accelerating the pace of smoking elimination. Implementation of new tobacco control policies are crucial in avoiding additional smoking-attributable burden in the coming decades and to ensure that the gains won over the past three decades are not lost.
fundingBloomberg Philanthropies and the Bill & Melinda Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.